Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym021 combinations in BTC and ESCC
NCT04641871Phase 1Completed
- Sponsor
- Symphogen
- Start
- Oct 2020
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of sym021, Sym022 and S095018 in biliary tract carcinoma (BTC) and Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Symphogen. Primary endpoints: Overall Response Rate up to 24 months, Incidence, Severity, and Relationship of Adverse Events and Serious Adverse Events and 1 more. Started Oct 2020; status: completed.
02
Drugs
sym021Sym022S095018
03
Conditions
biliary tract carcinoma (BTC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04641871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641871.